Canopy Growth (CGC) vs Eton Pharmaceuticals (ETON)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed Canopy Growth (CGC) over the past year, gaining 161.6% versus a loss of 44.7%. Over five years, ETON leads with a +950.9% price change compared with -99.3% for CGC. Eton Pharmaceuticals is the larger company by market cap ($1.56 billion vs $380.5 million), about 4.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGC | ETON |
|---|---|---|
| Share price | $0.8468 | $54.75 |
| Market cap | $380.47M | $1.56B |
| 1-day change | -3.39% | -0.24% |
| YTD return | -25.72% | +223.77% |
| 1-year return | -44.65% | +161.59% |
| 5-year return | -99.34% | +950.86% |
| P/E ratio (TTM) | — | 136.88 |
| Forward P/E | — | 21.22 |
| EPS (TTM) | $-0.45 | $0.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.38 | $66.37 |
| 52-week low | $0.81 | $14.27 |
| Distance from 52-week high | -64.42% | -17.51% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +41.71% | +29.68% |
| Average volume | 2.77M | 609.36K |
| Shares outstanding | 423.04M | 28.58M |
| Employees | 1,128 | 44 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Eton Pharmaceuticals is about 4.1 times larger than Canopy Growth by market value ($1.56B vs $380.47M).
- ETON has outperformed CGC by 206.2 percentage points over the past year.
About Canopy Growth
CGC stock →Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally. The company operates through two segments, Cannabis and Storz & Bickel.
Healthcare · Drug Manufacturers - Specialty & Generic · 1,128 employees
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Healthcare · Drug Manufacturers - Specialty & Generic · 44 employees
CGC vs ETON FAQ
Which is bigger, Canopy Growth or Eton Pharmaceuticals?
Eton Pharmaceuticals (ETON) is larger, with a market capitalization of $1.56B compared with $380.47M for Canopy Growth (CGC).
Which stock has performed better over the past year, CGC or ETON?
ETON returned +161.59% over the past 12 months, compared with -44.65% for CGC (price return, excluding dividends). Past performance does not predict future results.
Are Canopy Growth and Eton Pharmaceuticals in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.